arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Replimune Group, Inc.

REPL
$12.06 ▲ +0.51 (+4.46%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
37 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Replimune Group, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC -29.3%
FCF / Share None
Trailing P/E
Price / Book 6.0x
FCF Yield
Debt / Equity 0.50
info Valuation on last close. End-of-day price, Aug 7, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-73.22M
↑ +1.2%
FCF / Share Free cash flow per share
$-0.72
↑ +19.0%
Long-Term Debt Long-term obligations
$83.31M
↑ +74.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
3
Financial Health
29
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 37 quarters